well, the article, dated today, says "in a report published today..." i guess you have to trust the dateline.
Cowen says early Ph 1 IDO/PDD1 trial data seen. Out of 7 evaluable patients, ORR was 57%, disease control rate 100%
raised sales ^ but not EPS.
management should be reamed over this in a huge way.